Does the media favor CRL or ICLR?

In the previous week, Charles River Laboratories International had 16 more articles in the media than Icon. MarketBeat recorded 21 mentions for Charles River Laboratories International and 5 mentions for Icon. Icon's average media sentiment score of 1.03 beat Charles River Laboratories International's score of 0.36 indicating that Icon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Icon 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or CRL?

In the previous week, Bio-Techne had 6 more articles in the media than Charles River Laboratories International. MarketBeat recorded 27 mentions for Bio-Techne and 21 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.48 beat Charles River Laboratories International's score of 0.36 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 21 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRL or IQV?

In the previous week, IQVIA had 24 more articles in the media than Charles River Laboratories International. MarketBeat recorded 45 mentions for IQVIA and 21 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 1.44 beat Charles River Laboratories International's score of 0.36 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral IQVIA 38 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRL or RVTY?

In the previous week, Revvity had 11 more articles in the media than Charles River Laboratories International. MarketBeat recorded 32 mentions for Revvity and 21 mentions for Charles River Laboratories International. Revvity's average media sentiment score of 0.98 beat Charles River Laboratories International's score of 0.36 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Revvity 17 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Charles River Laboratories International (CRL) Competitors

$291.80 -4.61 (-1.56%)

As of 08/28/2026 03:58 PM Eastern

Compare

CRL vs. ICLR, TECH, A, IQV, and RVTY

Should you buy Charles River Laboratories International stock or one of its competitors? Charles River Laboratories International's main competitors and comparable companies include Icon (ICLR), Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Charles River Laboratories International compare to Icon?

Charles River Laboratories International (NYSE:CRL) and Icon (NASDAQ:ICLR) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Icon has a net margin of 3.99% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Icon	3.99%	8.02%	4.56%

In the previous week, Charles River Laboratories International had 16 more articles in the media than Icon. MarketBeat recorded 21 mentions for Charles River Laboratories International and 5 mentions for Icon. Icon's average media sentiment score of 1.03 beat Charles River Laboratories International's score of 0.36 indicating that Icon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Icon	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Icon has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.00B	3.48	-$144.34M	-$4.85	N/A
Icon	$8.29B	1.57	$229.34M	$4.26	39.91

Charles River Laboratories International presently has a consensus target price of $255.65, suggesting a potential downside of 12.39%. Icon has a consensus target price of $170.40, suggesting a potential upside of 0.22%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41

Charles River Laboratories International has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Icon has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Summary

Icon beats Charles River Laboratories International on 9 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.91
Charles River Laboratories International	$4.00B	3.48	-$144.34M	-$4.85	N/A

Bio-Techne has a net margin of 14.97% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Charles River Laboratories International	-5.96%	15.75%	6.51%

In the previous week, Bio-Techne had 6 more articles in the media than Charles River Laboratories International. MarketBeat recorded 27 mentions for Bio-Techne and 21 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.48 beat Charles River Laboratories International's score of 0.36 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	21 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bio-Techne presently has a consensus target price of $68.92, indicating a potential downside of 4.74%. Charles River Laboratories International has a consensus target price of $255.65, indicating a potential downside of 12.39%. Given Bio-Techne's higher possible upside, equities analysts plainly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Bio-Techne beats Charles River Laboratories International on 10 of the 15 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Agilent Technologies has a net margin of 19.53% compared to Charles River Laboratories International's net margin of -5.96%. Agilent Technologies' return on equity of 24.45% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Charles River Laboratories International	-5.96%	15.75%	6.51%

In the previous week, Agilent Technologies had 59 more articles in the media than Charles River Laboratories International. MarketBeat recorded 80 mentions for Agilent Technologies and 21 mentions for Charles River Laboratories International. Agilent Technologies' average media sentiment score of 1.17 beat Charles River Laboratories International's score of 0.36 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	47 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agilent Technologies presently has a consensus target price of $170.33, indicating a potential upside of 10.27%. Charles River Laboratories International has a consensus target price of $255.65, indicating a potential downside of 12.39%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.85
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Agilent Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$7.37B	5.92	$1.30B	$5.08	30.41
Charles River Laboratories International	$4.00B	3.48	-$144.34M	-$4.85	N/A

87.4% of Agilent Technologies shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 0.2% of Agilent Technologies shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Agilent Technologies beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Charles River Laboratories International has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Charles River Laboratories International presently has a consensus price target of $255.65, indicating a potential downside of 12.39%. IQVIA has a consensus price target of $241.88, indicating a potential downside of 7.14%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, IQVIA had 24 more articles in the media than Charles River Laboratories International. MarketBeat recorded 45 mentions for IQVIA and 21 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 1.44 beat Charles River Laboratories International's score of 0.36 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
IQVIA	38 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
IQVIA	8.10%	30.25%	6.54%

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.00B	3.48	-$144.34M	-$4.85	N/A
IQVIA	$16.98B	2.52	$1.36B	$8.06	32.32

Summary

IQVIA beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Charles River Laboratories International (NYSE:CRL) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Charles River Laboratories International currently has a consensus target price of $255.65, indicating a potential downside of 12.39%. Revvity has a consensus target price of $108.36, indicating a potential downside of 15.92%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, equities analysts clearly believe Charles River Laboratories International is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Charles River Laboratories International has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Revvity has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.00B	3.48	-$144.34M	-$4.85	N/A
Revvity	$2.86B	5.04	$241.20M	$2.10	61.37

In the previous week, Revvity had 11 more articles in the media than Charles River Laboratories International. MarketBeat recorded 32 mentions for Revvity and 21 mentions for Charles River Laboratories International. Revvity's average media sentiment score of 0.98 beat Charles River Laboratories International's score of 0.36 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revvity	17 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Revvity	8.16%	8.34%	5.01%

Summary

Charles River Laboratories International beats Revvity on 9 of the 16 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$13.92B	$10.11B	$7.20B	$24.18B
Dividend Yield	N/A	1.46%	2.54%	3.71%
P/E Ratio	-60.16	62.76	273.16	29.99
Price / Sales	3.48	111.64	605.16	22.60
Price / Cash	13.28	26.70	76.74	32.24
Price / Book	4.89	37.29	12.98	7.67
Net Income	-$144.34M	$56.67B	$3.48B	$1.07B
7 Day Performance	-1.16%	-1.52%	0.13%	-0.32%
1 Month Performance	24.08%	7.21%	7.08%	1.84%
1 Year Performance	78.70%	24.31%	24.67%	13.37%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	2.6157 of 5 stars	$291.80 -1.6%	$255.65 -12.4%	+78.7%	$13.92B	$4.00B	N/A	19,700	Trending News Insider Trade Analyst Revision
ICLR Icon	3.2438 of 5 stars	$168.93 +0.0%	$170.40 +0.9%	-4.5%	$12.93B	$8.25B	39.65	40,100	Analyst Forecast
TECH Bio-Techne	3.4783 of 5 stars	$72.38 +0.1%	$68.92 -4.8%	+32.4%	$11.34B	$1.22B	62.94	3,100	News Coverage Positive News Analyst Upgrade
A Agilent Technologies	4.5037 of 5 stars	$155.16 +0.3%	$160.24 +3.3%	+23.0%	$43.71B	$6.95B	31.16	18,100	Trending News Earnings Report Analyst Forecast
IQV IQVIA	3.7242 of 5 stars	$261.57 +0.8%	$241.88 -7.5%	+36.6%	$42.70B	$16.31B	32.45	93,000	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Do insiders and institutionals have more ownership in CRL or ICLR?

Is CRL or ICLR more profitable?

Does the media favor CRL or ICLR?

Which has higher valuation & earnings, CRL or ICLR?

Do analysts prefer CRL or ICLR?

Which has more volatility & risk, CRL or ICLR?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Which has more volatility and risk, TECH or CRL?

Which has higher earnings and valuation, TECH or CRL?

Is TECH or CRL more profitable?

Does the media prefer TECH or CRL?

Do insiders & institutionals have more ownership in TECH or CRL?

Do analysts prefer TECH or CRL?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Is A or CRL more profitable?

Does the media prefer A or CRL?

Do analysts recommend A or CRL?

Which has more volatility and risk, A or CRL?

Which has preferable earnings and valuation, A or CRL?

Do institutionals & insiders believe in A or CRL?

Summary

How does Charles River Laboratories International compare to IQVIA?

Do institutionals and insiders believe in CRL or IQV?

Which has more volatility & risk, CRL or IQV?

Do analysts recommend CRL or IQV?

Does the media refer more to CRL or IQV?

Is CRL or IQV more profitable?

Which has higher earnings and valuation, CRL or IQV?

Summary

How does Charles River Laboratories International compare to Revvity?

Do analysts recommend CRL or RVTY?

Do institutionals & insiders believe in CRL or RVTY?

Which has more volatility and risk, CRL or RVTY?

Which has preferable valuation and earnings, CRL or RVTY?

Does the media refer more to CRL or RVTY?

Is CRL or RVTY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools